Circulating Soluble Receptor For Advanced Glycation End Products (sRAGE) And Left Ventricular Hypert-Rophy In Patients With Early Chronic Kidney Disease

Objective:To investigate serum sRAGE levels and the relationship between sRAGE with left ventricular hypertrophy (LVH) in early chronic kidney disease(CKD).Methods: Between December2012and July2013,Selected70cases of early chronic kidney disease (GFR≥30ml·min1-1·73m-2) for the study group, and50healthy subjects as control group.Patients with left ventricular mass index, according to the study group was divided into early chronic kidney disease with left ventricular hypertrophy (CKD-LVH group) with early chronic kidney disease non-LVH group (CKD-NLVH group).Collection of clinical data and biochemical parameters, by ELISA serum levels of sRAGE,Using echocardiography to measure cardiac lumen diameter and left ventricular mass index is calculated. SRAGE level analysis of each group and its relationship with left ventricular hypertrophy.Results:CKD group sRAGE levels higher(P<0.05),40patients had left ventricular hypertrophy in CKD group,CKD-LVH group sRAGE levels below the CKD-NLVH group (P<0.05), sRAGE was related inversely with LVMI(r=-0.362,P<0.05), Logistic regressive analysis revealed that sRAGE correlated with LVH in early CKD.Conclusion:sRAGE is higher in early CKD patients than in healthy controls,and it reduces in CKD patients with LVH. sRAGE was related inversely with LVMI.sRAGE had a significant correlation with LVH,sRAGE may be important protection factors of LVH in the patients with early CKD.